Webcast ImageWebcast
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference  (Replay)
03/21/17 at 3:55 p.m. ET
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference
Tuesday, March 21, 2017 3:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
December 21, 2011BioTime Signs Agreement with USCN Life Science to Source Antibody-Based Products
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 21, 2011-- BioTime, Inc. (NYSE Amex: BTX) today announced agreements with USCN Life Science, Inc. (USCN) of Wuhan, China, granting BioTime an option to license USCN’s antibody-producing cell lines and certain related technology that may be used by BioTime and its subsidiary OncoCyte Corporation for the large-scale manufacture of the antibody components of PanC-DxTM. PanC-DxTM is a novel diagnostic technol... 
Printer Friendly Version
December 16, 2011BioTime's Subsidiary OncoCyte Corporation Announces Plans for the Novel Pan-Cancer Diagnostic Product PanC-DxTM
- A novel blood-based screening method for the early detection of many common human cancers such as those of the breast, colon, and lung - ALAMEDA, Calif., Dec 16, 2011 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and BioTime's subsidiary OncoCyte Corporation today announced plans for the development of PanC-DxTM, a novel diagnostic device discovered at BioTime and OncoCyte to detect the presence of various human cancers, including cancers of the br... 
Printer Friendly Version
December 12, 2011BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 12, 2011-- BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the successful completion of ISO 10993 biocompatibility studies for HyStem®-Rx. These tests, as prescribed by the International Organization for Standardization for permanent implantable medical devices, are required by the United States Food and Drug... 
Printer Friendly Version
November 29, 2011BioTime, Inc. Appoints Andrew C. von Eschenbach, M.D. to its Board of Directors
ALAMEDA, Calif., Nov 29, 2011 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) and BioTime's subsidiary, OncoCyte Corporation, today announced they have each appointed Dr. Andrew von Eschenbach to their boards of directors. Dr. von Eschenbach is the President of Samaritan Health Initiatives, Inc., a health care policy consultancy, and is an Adjunct Professor at University of Texas MD Anderson Cancer Center. From September of 2005 to January 2009, Dr. ... 
Printer Friendly Version
November 14, 2011BioTime Cell Information Now Available in GeneCards(R)
- New GeneCards® release includes gene expression markers for BioTime’s ACTCellerateTM cell lines - ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2011-- BioTime, Inc. (NYSE Amex: BTX) and XenneX, Inc. today announced the inclusion of cell identification data in GeneCards® 3.07 available at www.genecards.org. The new GeneCards release identifies BioTime’s ACTCellerate™ human embryonic progenitor (hEP) cell lines that... 
Printer Friendly Version
November 08, 2011BioTime Announces Third Quarter 2011 Financial Results and Recent Corporate Accomplishments
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments. "The key to building the leading company in the emerging field of regenerative medicine is the identification of a strategy for the rapid development and commercialization of significant therapeutic products. Our s... 
Printer Friendly Version
October 25, 2011BioTime CEO Michael D. West to Present Keynote Address at Translational Strategies for Tissue Engineering Conference
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present a keynote address at the Translational Strategies for Tissue Engineering Conference in Boston, MA at 9:30 a.m. EDT on Tuesday, November 1, 2011. Dr. West's presentation will be titled: "Cell and Matrix: Translational Strategies in the Era of Pluripotency." He will discu... 
Printer Friendly Version
October 13, 2011BioTime Publishes Paper Describing First Complete Sequencing of the Nuclear DNA of Five Clinical-Grade Human Embryonic Stem Cell Lines
Study shows normal gene content of the cells and potential suitability for use in the manufacture of human therapeutics BioTime, Inc. (NYSE Amex:BTX) announced today the publication in the peer-reviewed journalStem Cell Research of the complete genome sequence analysis of five clinical-grade human embryonic stem cell lines. "Evaluating the Genomic and Sequence Integrity of Human ES Cell Lines: Comparison to Normal Genomes" is the first such analysis of the entire genome of huma... 
Printer Friendly Version
October 10, 2011BioTime CEO Michael D. West to Present at GTC 2011 5th Advances in Stem Cell Discovery & Development Conference
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the GTC 2011 5th Advances in Stem Cell Discovery & Development Conference in San Diego, California at 9:10 a.m. PDT on Thursday, October 20, 2011. Dr. West will speak on recent trends in the stem cell industry and BioTime's strategies in product development. The ... 
Printer Friendly Version
October 04, 2011BioTime Announces Appointment of Chief Financial Officer
- Peter Garcia brings 25 years of public and private life science and high-tech finance experience - BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the appointment of Peter Garcia to the position of Chief Financial Officer. Mr. Garcia, age 50, will lead the accounting, finance, and investor relations functions of the Company, will report directly to Michael D. West, Ph.D., President an... 
Printer Friendly Version
September 29, 2011BioTime CEO Dr. Michael West to Present at 2011 World Stem Cell Summit
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 2011 World Stem Cell Summit in Pasadena, California at 2:30 p.m. PDT on Monday, October 3, 2011. Dr. West will be presenting "Unleashing Regenerative Medicine to Extend the Healthy Lifespan: Technological Issues and Commercial Opportunities" which will include a... 
Printer Friendly Version
September 12, 2011BioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2011
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Stem Cells USA & Regenerative Medicine Congress 2011 in Boston, MA at 9:35 a.m. EDT on Wednesday, September 14, 2011. Dr. West's presentation, "A roadmap for successful commercialization of hES and iPS cell-based therapies," will include a discussion of the n... 
Printer Friendly Version
September 06, 2011BioTime Enters into Worldwide License Agreement with Cornell University to Develop and Commercialize Vascular Cells Derived from Human Embryonic Stem Cells
Technology to be utilized in product development by BioTime's subsidiaries OncoCyte Corporation and ReCyte Therapeutics, Inc. BioTime, Inc. (NYSE Amex:BTX) today announced it has entered into an exclusive license agreement with Cornell University for the worldwide development and commercialization of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells. Published last year in Nature Biotechno... 
Printer Friendly Version
September 01, 2011BioTime CEO Michael D. West to Present at Rodman & Renshaw 13th Annual Healthcare Conference
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Rodman & Renshaw 13th Annual Healthcare Conference at 4:05 p.m. EDT on Tuesday, September 13, 2011. The conference will be held at The Waldorf Astoria Hotel in New York. Dr. West will provide updates on product development by BioTime and its subsidiaries Onc... 
Printer Friendly Version
August 24, 2011BioTime's Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing
Capital to be utilized in advancing the development of novel cancer diagnostic and therapeutic products BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced its majority-owned subsidiary OncoCyte Corporation (OncoCyte) has received a new round of equity financing to fund expansion of its development of novel proprietary diagnostics and therapeutics for cancer in humans. The financing included... 
Printer Friendly Version
August 19, 2011BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines
ESI-035, ESI-049, ESI-051 and ESI-053 approved for use in federally funded research BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that four human embryonic stem (hES) cell lines: ESI-035, ESI-049, ESI-051 and ESI-053, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. This approval... 
Printer Friendly Version
August 09, 2011BioTime Announces Second Quarter 2011 Financial Results and Corporate Developments
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the quarter ended June 30, 2011 and provided an update on corporate developments. For the quarter ended June 30, 2011, total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income) was $756 thousand, up 11% from $680 thousand for the same period on... 
Printer Friendly Version
July 21, 2011BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2011
BioTime, Inc. (NYSE Amex:BTX) announced today that Chief Executive Officer Michael D. West, Ph.D. will present at the Agora Financial Investment Symposium 2011 in Vancouver, British Columbia, Canada on Thursday, July 28, 2011. The title of Dr. West's presentation will be "The Stem Cell Revolution: Designing First-in-Class Therapies for Age-Related Degenerative Disease." In this presentation Dr. West will describe new corporate developments at BioTime and its subsidiaries. Dr. West's pres... 
Printer Friendly Version
July 19, 2011BioTime Announces the Issuance of a Second U.S. Glycosan Hydrogel Patent
BioTime, Inc. (NYSE Amex: BTX) announced today the issuance of United States patent number 7,981,871 titled "Modified Macromolecules and Associated Methods of Synthesis and Use," covering aspects of the composition of Glycosan hydrogels. The patent and related patent family members, assigned to the University of Utah, are licensed to BioTime's subsidiary OrthoCyte Corporation for the manufacture of research products and for therapeutic uses when combined with human cells by BioTime or it... 
Printer Friendly Version
July 15, 2011BioTime Receives $335,900 SBIR Grant
HyStem® microcarrier hydrogels to be developed for stem cell research and therapeutic applications BioTime, Inc. (NYSE Amex:BTX) today announced it has been awarded a 10-month, $335,900 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop HyStem® microcarriers for the propagation of human stem cells and as a means of cell delivery for human clinical applications. "Hundreds of millions of stem cells will be required for many of the cl... 
Printer Friendly Version
June 29, 2011BioTime Announces Appointment of Chief Commercial Officer
William P. Tew, Ph.D. will lead commercial efforts for BioTime and its subsidiaries BioTime, Inc. (NYSE Amex:BTX) today announced the appointment of its Vice President of Business Development, William P. Tew, Ph.D., to the additional position of Chief Commercial Officer. Dr. Tew will be responsible for the commercial operations of the BioTime family of companies and for near-term product development activities. Dr. Tew's commercial team will expand the depth and breadth of the BioTime c... 
Printer Friendly Version
June 09, 2011BioTime Reports First Complete Sequencing of the Nuclear Genome of Five GMP-Compliant Human Embryonic Stem Cell Lines at Jefferies 2011 Global Healthcare Conference
Complete sequencing of DNA shows normality of the cells and their suitability for clinical use BioTime, Inc. (NYSE Amex:BTX) Chief Executive Officer, Michael D. West, Ph.D., will present today at the Jefferies 2011 Global Healthcare Conference in New York City at 1:00 p.m. EDT. His presentation will disclose commercial progress in each of the Company's seven subsidiaries. Included in this update will be information on the first complete sequencing of the DNA of five human embryonic stem... 
Printer Friendly Version
June 03, 2011BioTime Receives NIH Approval for Two GMP Human Embryonic Stem Cell Lines
ESI-014 and ESI-017 approved for use in Federally funded research BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that two human embryonic stem (hES) cell lines, ESI-014 and ESI-017, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry. This approval opens the door to the use of these cell ... 
Printer Friendly Version
June 02, 2011BioTime CEO Dr. Michael West to Present at the Jefferies 2011 Global Healthcare Conference
BioTime, Inc. (NYSE Amex: BTX) Chief Executive Officer, Michael D. West, Ph.D., is scheduled to speak during the Jefferies 2011 Global Healthcare Conference June 6-9, 2011 in New York City. Dr. West will present on Thursday, June 9 at 1:00 p.m. EDT. He will discuss BioTime's business in regenerative medicine and provide an update on recent progress in developing its stem cell-based products. A link to the live webcast of the company's presentation will be available in the investors sect... 
Printer Friendly Version
May 10, 2011BioTime Announces Issuance of U.S. Glycosan Hydrogel Patent
BioTime, Inc. (NYSE Amex:BTX) announced today the issuance of United States patent number 7,928,069 covering certain aspects of the composition of Glycosan hydrogels. The patent and related patent family members, assigned to the University of Utah, are licensed to BioTime's subsidiary OrthoCyte Corporation for the manufacture of research products and for therapeutic uses when combined with human cells by BioTime or its subsidiaries. The patent is of strategic value to the BioTime family ... 
Printer Friendly Version
May 05, 2011BioTime Announces First Quarter 2011 Financial Results and Corporate Developments
BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine and blood plasma volume expander solutions, today reported financial results for the quarter ended March 31, 2011 and provided an update on corporate developments. For the quarter ended March 31, 2010, total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income) was $825 t... 
Printer Friendly Version
May 03, 2011BioTime Initiates Clinical Development Program for HyStem®-Rx as a Cell Delivery Device for Reconstructive Surgery and Other Cell-Based Therapies
BioTime, Inc. (NYSE Amex:BTX) announced today that it has elected to seek regulatory approval of HyStem®-Rxas an implantable cell delivery vehicle that can be used to significantly improve outcomes in reconstructive surgery and potentially a wide array of other cell-based therapies. Such applications may include numerous cell transplant procedures currently being developed in which a patient's own adult stem cells are utilized. Similarly, once newer cell replacement products derived from... 
Printer Friendly Version
April 12, 2011BioTime Presents Data at FABS 2011 on the Restoration of Cell Lifespan Using iPS Cell Technology
Restoration of Replicative Lifespan in Five Human Cell Types Validates Previous Published Report of Reversal of Developmental Aging by Transcriptional Reprogramming BioTime, Inc. (NYSE Amex:BTX) and its subsidiary ReCyte Therapeutics, Inc. announced that today, BioTime CEO Dr. Michael West will present at the French-American Biotech Symposium(FABS 2011) on "New Therapeutic Approaches of Aging" held in San Francisco, CA, showing data for the first time on the restoration of cell lif... 
Printer Friendly Version
April 05, 2011BioTime and XenneX Form LifeMap Sciences, Inc. to Create Roadmap for Regenerative Medicine
Database to promote the marketing of BioTime's research products BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has formed LifeMap Sciences, Inc., in collaboration with XenneX, Inc. LifeMap Sciences will develop and commercialize a database of the thousands of cell lineages branching from embryonic stem cells, and their molecular markers. LifeMap Sciences plans to make ... 
Printer Friendly Version
March 22, 2011BioTime Announces the Closing of the Merger of Glycosan BioSystems with OrthoCyte Corporation
William P. Tew, Ph.D. Becomes Vice President, Business Development of BioTime and OrthoCyte BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the fields of stem cells, regenerative medicine and blood plasma volume expanders today announced it has completed the merger of Glycosan BioSystems, Inc. into BioTime's wholly-owned subsidiary OrthoCyte Corporation. The definitive merger agreement was previously announced on February 14, 2011. OrthoCyt... 
Printer Friendly Version
March 15, 2011BioTime Announces Fourth Quarter and Fiscal Year 2010 Financial Results and Corporate Developments
89% Increase in Total Revenue Year-over-Year for the Quarter 91% Increase in Total Revenues Year-over-Year for the Fiscal Year BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine and blood plasma volume expander solutions, today reported financial results for the quarter and year ended December 31, 2010 and provided an update on corporate developments. Fourth Quarter 2010 For the quarter ended ... 
Printer Friendly Version
March 04, 2011BioTime CEO Michael West to Present at French-American Biotech Symposium, San Francisco, April 11-12, 2011
Update on ReCyte™ technology for resetting telomere length and its application in cardiovascular disease BioTime, Inc. (NYSE Amex:BTX) and its subsidiary ReCyte Therapeutics, Inc. announced today that BioTime CEO Dr. Michael West will present at the French-American Biotech Symposium on "New Therapeutic Approaches of Aging" in San Francisco, April 11-12, 2011. Dr. West will speak on "Resetting Telomere Length using Transcriptional Reprogramming and its Application in Age-Related Degenera... 
Printer Friendly Version
February 14, 2011BioTime Announces Agreement To Acquire Glycosan BioSystems
Acquisition to accelerate BioTime's development of tissue engineered therapeutic products and expand research product portfolio BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March ... 
Printer Friendly Version
January 28, 2011BioTime Acquires Assets of Cell Targeting, Inc.
--Proprietary technology "paints" cells with peptides to target them to diseased tissues-- BioTime, Inc. (NYSE Amex:BTX) today announced that it has acquired substantially all the assets of Cell Targeting, Inc. (CTI), a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine. The technology acquired from CTI uses peptides selected for their ability to adhere to diseased tissues. By coating or "painting" these peptides onto the surfaces of therapeutic cel... 
Printer Friendly Version
January 21, 2011BioTime Launches New Stem Cell Lines in Anticipation of President Obama's Removal of Restrictions on Federal Funding of Embryonic Stem Cell Research
New Cell Line Products to be Presented at Stem Cells World Conference BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D., will deliver a presentation on January 21, 2009 at the Select Biosciences Stem Cells World Congress meeting in Palm Springs, California. Dr. West's presentation is titled "Embryomics: High Throughput Generation and Mapping of Embryonic Progenitors." This year's conference will focus on new technologies in stem cell research and developm... 
Printer Friendly Version
January 10, 2011BioTime's CEO Michael West to Present Preclinical Data on OTX-CP03 and OTX-CP07 for the Treatment of Osteoarthritis at STEM 2011 in Gurgaon, India
BioTime, Inc. (NYSE Amex:BTX) and its subsidiary OrthoCyte Corporation announced today that BioTime's CEO Dr. Michael West will present at STEM 2011 in Gurgaon, India on January 31, 2011. The conference is the 7th Annual Conference on Biotechnology sponsored by the Society for Regenerative Medicine and Tissue Engineering. Dr. West's presentation titled, "Progress in the commercialization of human embryonic stem cell technology" will disclose animal preclinical data on the ... 
Printer Friendly Version
January 03, 2011BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders
$4 Million Equity Financing Company Plans Near-Term Commercialization of iPS Cell Banking Services that Reverse the Developmental Aging of Human Cells BioTime, Inc. (NYSE Amex:BTX) today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 mill... 
Printer Friendly Version